|The KAT2A kat2a (Catalog #MBS140349) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s Histone acetyltransferase KAT2A can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Western Blot (WB), Immunofluorescence (IF).
KAT2A antibody has been tested by ELISA, Western blot and Immunofluorescence analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results. Recommended dilution range for Western blot analysis and Immunofluorescence is 1:250 ~ 500.Recommended starting dilution is 1:250. Researchers should empirically determine the suitability of the KAT2A kat2a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The KAT2A kat2a product has the following accession number(s) (GI #153791535) (NCBI Accession #NP_066564.2). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Introduction: KAT2A (GCN5L2 or GCN5) is a histone acetyltransferase (HAT), which functions mainly as a transcriptional activator. GCN5L2 may be one of the enzymes involved in acetylation in vivo. GCN5 is expressed primarily in the embryo and newborn and is crucial for normal embryonic development. Hence, KAT2A appears to be significant for differentiation of embryonic-derived preadipocytes. GCN5 also functions as a repressor of NF-kappa-B by promoting ubiquitination of the NF-kappa-B subunit RELA in a HAT-independent manner. Loss of GCN5L2 leads to a high occurrence of apoptosis in the KAT2A mutants, which begins before the onset of morphological abnormality.
Immunogen: Anti-human KAT2A mAb, is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with recombinant human KAT2A amino acids 411-837 purified from E Coli. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing KAT2A are readily searchable from our website. Different antibodies against the same target such as KAT2A may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. KAT2A also interacts with the following gene(s): MYC, SUPT3H, TADA2A, TAF10, TAF4, TRRAP. The following patways have been known to be associated with this gene. Body Weight Changes, Brain Diseases, Fatty Liver, Fibrosis, Kidney Diseases, Liver Diseases, Musculoskeletal Abnormalities, Nerve Degeneration, Nervous System Diseases, Ovarian Diseases are some of the diseases may be linked to Mouse Anti Human Histone acetyltransferase KAT2A.